Government Weighs Break Clause Option in Palantir NHS Contract

Key Takeaways

The UK government is considering activating a break clause in the £330m contract with Palantir for the NHS federated data platform.
Some NHS officials warn that terminating the contract could be disruptive, though they believe it is feasible.
Palantir defends its platform, stating it has significantly improved patient care and operational efficiency.

Potential Changes to NHS Contract with Palantir

Government officials in the UK are reportedly contemplating the activation of a break clause in the £330 million contract with the US software firm Palantir, responsible for the NHS federated data platform (FDP). This platform integrates data across various NHS organizations, with a scheduled review in early 2027. However, the Financial Times has indicated that discussions regarding an early exit from this contract are underway.

A senior government figure stated, “we are confident we could do it if we wanted to,” emphasizing that this exploration is not driven by current dissatisfaction with Palantir’s services. The motivation stems from concerns over the company’s surveillance software being used by organizations like the U.S. Immigration and Customs Enforcement. In light of this, the British Medical Association has urged NHS doctors to limit their reliance on the FDP.

The Department of Health and Social Care has defended the platform, highlighting its role in improving patient care, speeding up cancer diagnoses, and ensuring increased treatment capacity. They reassured that each hospital trust and integrated care board maintains its own instance of the platform, allowing complete control over data access.

Experts from various NHS trusts have conveyed mixed sentiments about the implications of switching away from Palantir. Will Monaghan from University Hospital Leicester noted that while it’s feasible to transition to another platform, doing so would be highly disruptive. Kavitha Saravanakumar from NHS North West London echoed this sentiment but mentioned that while difficult, her organization could manage the transition.

Any decision to implement the break clause would precede an independent evaluation of the FDP’s performance, which is set to last up to three years. Cybersecurity specialist Dr. Saif Abed emphasized the need for overhauling NHS procurement processes, enabling organizations to remove underperforming suppliers without fear of legal repercussions.

Concerns were further elaborated by Dr. Jessica Morley of Yale, who argued that any health data initiative should meet specific evaluative criteria. She posited that the FDP has not met these standards, suggesting that invoking the break clause could present a chance to adopt a more effective approach.

In response to these discussions, Louis Mosley, Palantir’s executive vice-chair in the UK, defended the company’s track record. He argued that calls for contract termination stem from ideological motivations that could ultimately hinder patient care and the NHS’s ability to tackle pressing challenges. He cited the platform’s successes, including 110,000 additional surgeries, a 15% reduction in patient discharge delays, and improved cancer diagnosis times. According to him, the FDP has achieved important milestones, earning a green delivery rating in contrast to many major government programs, and is expected to generate £150 million in benefits by the decade’s end.

Digital Health News has reached out to NHS England for further comment on the situation.

The content above is a summary. For more details, see the source article.